Tag: Chronic therapy

In November 2023, the U.S. Food and Drug Administration (FDA) officially approved tirzepatide (marketed as Zepbound) for chronic weight management, directly answering the question: **is tirzepatide approved for long-term use?** for this specific purpose. This approval was based on robust clinical trial data showing sustained efficacy over extended periods, highlighting a significant shift towards considering obesity and related conditions as chronic diseases requiring long-term treatment.

For patients with primary immunodeficiency, Intravenous Immunoglobulin (IVIG) therapy is typically a lifelong and life-saving necessity. However, whether or not you have to take IVIG forever depends on the specific condition being treated, with some autoimmune diseases allowing for eventual tapering or discontinuation.